Table 1. Characterization of the 8... | American Society of Hematology

Table 1.

Characterization of the 8 IBT-study patients with transfusion-dependent homozygous β-thalassemia

Patient no.	Duration of treatment (d)	Sex	Age (y)	Country of origin	DFO (mg/kg per day)	Ferritin^*(μg/L)	anti-HCV +/−	β-globin mutation	^Gγ-158 C → T	Parental HbF (%)
Patient no.	Duration of treatment (d)	Sex	Age (y)	Country of origin	DFO (mg/kg per day)	Ferritin^*(μg/L)	anti-HCV +/−	β-globin mutation	^Gγ-158 C → T	Mother^†	Father
1	224	M	8	Turkey	35	1969 (1618-2140)	−	IVS1 + 110 G → A/ IVS1 + 110 G → A	+/+	<0.5	<0.5
2	384	M	13	Turkey	25	3858 (3360-4520)	+	NS39/NS39	−/−	1.3	<0.5
3	224	F	19	Turkey	55	1493 (1290-1772)	−	IVS1 + 110 G → A/ FS8/9(+G)	−/−	<0.5	<0.5
4	224	F	25	Greece	75	2325 (1120-3409)	−	IVS1 + 110 G → A/ IVS2 + 745 C → G	−/−	<0.5	<0.5
5	370	M	17	Jordan	75	3702 (2680-4293)	+	NS37/−86 C → G	−/−	1.9	0.6
6	126	M	24	Turkey	75	9117 (6424-9864)	+	—	—	—	—
7	224	F	14	Turkey	60	1453 (1270-1849)	+	IVS1 + 110 G → A/ IVS2 + 1 G → A	+/−	<0.5	0.9
8	224	M	20	Turkey	35	6881 (4730-9026)	+	NS39/IVS2 + 1 G → A	+/−	<0.5	<0.5

Patient no.	Duration of treatment (d)	Sex	Age (y)	Country of origin	DFO (mg/kg per day)	Ferritin^*(μg/L)	anti-HCV +/−	β-globin mutation	^Gγ-158 C → T	Parental HbF (%)
Patient no.	Duration of treatment (d)	Sex	Age (y)	Country of origin	DFO (mg/kg per day)	Ferritin^*(μg/L)	anti-HCV +/−	β-globin mutation	^Gγ-158 C → T	Mother^†	Father
1	224	M	8	Turkey	35	1969 (1618-2140)	−	IVS1 + 110 G → A/ IVS1 + 110 G → A	+/+	<0.5	<0.5
2	384	M	13	Turkey	25	3858 (3360-4520)	+	NS39/NS39	−/−	1.3	<0.5
3	224	F	19	Turkey	55	1493 (1290-1772)	−	IVS1 + 110 G → A/ FS8/9(+G)	−/−	<0.5	<0.5
4	224	F	25	Greece	75	2325 (1120-3409)	−	IVS1 + 110 G → A/ IVS2 + 745 C → G	−/−	<0.5	<0.5
5	370	M	17	Jordan	75	3702 (2680-4293)	+	NS37/−86 C → G	−/−	1.9	0.6
6	126	M	24	Turkey	75	9117 (6424-9864)	+	—	—	—	—
7	224	F	14	Turkey	60	1453 (1270-1849)	+	IVS1 + 110 G → A/ IVS2 + 1 G → A	+/−	<0.5	0.9
8	224	M	20	Turkey	35	6881 (4730-9026)	+	NS39/IVS2 + 1 G → A	+/−	<0.5	<0.5

Median and interquartile range of ferritin values over a period of 1 year before the trial period.

None of the mothers were pregnant at the time the blood was drawn.